XGXiaolong Gao

Xiaolong Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaolong Gao has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Bingbo Zhang

    Department of Radiology, Tongji Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai, China

    2 shared publications
  • Weitao Yang

    Department of Radiology, Tongji Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering and Nano Science, School of Medicine, Tongji University 1 , Shanghai 200065, China

    2 shared publications
  • Weiwei Zeng

    Department of Radiology, Tongji Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering and Nano Science, School of Medicine, Tongji University 1 , Shanghai 200065, China

    2 shared publications
  • Aijun Shen

    Department of Medical Imaging, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China (Y.L., W.W., Y.J., Y.X., Y.L., D.C., Z.H., A.S.); Institute of Medical Imaging Artificial Intelligence, Tongji University School of Medicine, Shanghai, China (Y.L., W.W., Y.J., Y.X., Y.L., D.C., Z.H., A.S.).

    1 shared publication
  • Bo Deng

    Department of Radiology, Shanghai Fifth Rehabilitation Hospital, Shanghai, China

    1 shared publication
  • Chao Lin

    Institute for Translational Medicine

    1 shared publication

Latest Publications

  • Open Access

    Predicting recurrent chest pain in patients with myocardial bridging using explainable machine learning: a multicenter study integrating CT-derived functional and inflammatory imaging biomarkers

    by Jingquan Hu, Kuigang He, Jing Luo, Rui Xia, Yufeng Zhang, Xiaolong Ma, Zhihong Shao, Xiaolong Gao

    Myocardial bridging (MB) is a common congenital coronary anomaly that is increasingly recognized as a potential cause of myocardial ischemia and recurrent


  • A nomogram based on MRI radiomics features of mesorectal fat for diagnosing T2- and T3-stage rectal cancer

    by Bo Deng, Qian Wang, Yuanqing Liu, Yanwei Yang, Xiaolong Gao, Hui Dai

    Purpose To develop and validate a nomogram for the preoperative diagnosis of T2 and T3 stage rectal cancer using MRI radiomics features of mesorectal fat. Methods The data of 288 patients with T2 and T3 stage rectal cancer were retrospectively collected. Radiomics features were extracted from the lesion region of interest (ROI) in the MRI high-resolution T2WI, apparent diffusion coefficient (ADC), and diffusion-weighted imaging (DWI) sequences. After using ICC inter-group consistency analysis and Pearson correlation analysis to reduce dimensions, LASSO regression analysis was performed to select features and calculate Rad-score for each sequence. Then, Combined_Radscore and nomogram were constructed based on the LASSO-selected features and clinical data for each sequence. Receiver operating characteristic curve (ROC) area under the curve (AUC) was used to evaluate the performance of the Rad-score model and nomogram. Decision curve analysis (DCA) was performed to evaluate the clinical usability of the radiomics nomogram, which were combined with calibration curves to evaluate the prediction accuracy. Results The nomogram based on MRI-report T status and Combined_Radscore achieved AUCs of 0.921 and 0.889 in the training and validation cohorts, respectively. Conclusion The nomogram can be stated that the radiomics nomogram based on multi-sequence MRI imaging of the mesorectal fat has excellent diagnosing performance for preoperative differentiation of T2 and T3 stage rectal cancer.


  • A Smart Responsive Nanotheranostic System for MRI of Tumor Response to Immunotherapy and Enhanced Synergism of Thermo‐Immunotherapy

    by Minghua Li, Chao Lin, Aijun Shen, Xiaolong Ma, Jiong Ni, Jiaqi Wu, Wei Wang, Peijun Wang, Xiaolong Gao

    The challenges associated with the assessment of immune checkpoint inhibitor (ICI) therapy and low immunotherapy response observed in patients with poorly immunogenic tumors are addressed. A smart‐responsive nanoprobe MZF@Gd is synthetized based on magnetic resonance tuning (MRET). The nanoprobe is designed to be targeted and cleaved by granzyme B, a marker of cytotoxic T‐cell activation. MZF@Gd consisted of superparamagnetic Mn‐ and Zn‐doped ferrite magnetic nanoparticles (MZF‐MNPs) with a magnetocaloric effect and a paramagnetic contrast agent gadolinium‐diethylenetriamine penta‐acetic acid (Gd‐DTPA). These components are connected by the granzyme B substrate peptides. The activation of the T1WI signal through MRET, following the cleavage of the probe by granzyme B, enabled the accurate evaluation of the ICI therapeutic effect. Subsequently, an active‐targeting magnetothermally responsive nanotheranostic agent FA‐P(MZF@Gd/JQ1) is fabricated. This agent incorporated the MRET probe MZF@Gd, JQ‐1 (an inhibitor of PD‐L1), the thermosensitive copolymer PCL‐b‐P(MEO2MA‐co‐OEGMA), and folic acid on the surface. Nanotheranostic agents killed tumor cells through magnetocaloric effects, stimulated antitumor immunity, and regulated the drug release, thereby achieving a synergistic effect between hyperthermia and immunotherapy. Moreover, MZF@Gd released from the agent sensitively detected the presence of granzyme B at the tumor site, thereby enabling an effective assessment of therapeutic efficacy.


  • Open Access

    pH/thermal dual-responsive multifunctional drug delivery system for effective photoacoustic imaging-guided tumor chemo/photothermal therapy

    by Jun Wang, YanYan Wu, Kai Liu, Weitao Yang, Weiwei Zeng, Xiaolong Gao, ShiYuan Liu, Bingbo Zhang

    The development of a combination of chemo/photothermal therapy could overcome the limitations of single-modality therapy and enhance therapeutic efficacy. In this study, a pH/thermal dual-responsive multifunctional drug delivery system with dual-drug loading and enhanced chemo/photothermal therapy is developed based on polydopamine-coated mesoporous silica-gold nanorods ([email protected]). Nanoscale mesoporous silica-gold nanorods encapsulating doxorubicin (DOX) are designed as a core and then modified by polydopamine. The PDA shell not only conjugates with another anticancer bortezomib (Btz) to form pH-sensitive bond through boronic acid and catechol but also acts as a gatekeeper to control the release of doxorubicin and enhance the photothermal effect. Such a nanocarrier not only acts as a contrast agent for PA imaging but also serves as a therapeutic agent for enhanced chemo/photothermal therapy. The DOX and Btz could be released in an on-demand mode under near-infrared light irradiation and acid environment. The tumor size and location could be observed via PA imaging after intravenous injection into 4T1-bearing mice. Compared with [email protected], [email protected] exhibit an increased near-infrared (NIR) absorption at 808 nm and an enhanced photothermal effect. The integrated D/[email protected] nanoparticles show higher cell apoptosis and enhanced tumor treatment efficacy in vitro and in vivo in comparison with single chemotherapy or photothermal therapy. Combined together, D/[email protected] show pH/thermal-responsive controlled-release and synergistic chemo/photothermal therapy for tumor.


  • Open Access

    Double Drug-Loaded and pH/Thermal Sensitive Multifunctional Drug Delivery System for Tumor Photoacoustic Imaging-Guided Enhanced Chemo/Photothermal Therapy

    by Jun Wang, Na Chen, Kai Liu, Yu Tu, Weitao Yang, Xiaolong Gao, Weiwei Zeng, Bingbo Zhang

    Background: Owing to the tunability of longitudinal surface plasmon resonance (LSPR), ease of synthesizing small size and excellent stability, AuNRs have been developed as photothermal agents for cancer therapy. However, PTT alone could not kill cancer cells completely due to the local heterogeneous distribution of heat in tumors, penetration depth of light, light scattering and absorption. In addition, the treatment systems based on AuNRs hold disadvantages of loading one antitumor drug or a low therapeutic efficiency. Therefore, the construction of the AuNRs theranostic system to achieve imaging-guided dual drug delivery and enhanced photothermal therapy for tumor still remains a great challenge.Methods: The AuNRs were prepared using a seedless method. A mesoporous silica shell layer was coated on the surface of the AuNRs by sol-gel method. Double anticancer drugs, DOX and Btz, were loaded into the AuNRs@MSN nanoparticles through physical absorption and covalent conjugation, respectively.Results: The release of DOX and Btz is found pH/thermal dual responsive in vitro. Compared with AuNRs@MSN, PDA-AuNRs@MSN exhibits an increased near-infrared (NIR) absorption at 808 nm and an enhanced photothermal effect. In contrast to chemotherapy or photothermal therapy alone, the integrated D/B-PDA-AuNRs@MSN nanoparticles show higher cell apoptosis and enhanced tumor treatment efficacy in vitro and in vivo.Conclusions: In this study, we designed a double-drug loading, enhanced chemo/photothermal therapy and pH/thermal responsive drug delivery system for photoacoustic (PA) imaging-guided tumor therapy. We believe that the multifunctional D/B-PDA-AuNRs@MSN theranostic probe could serve as an effective probe for the treatment of cancers.